• Explore /
  • Poster
  • / A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.

A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.

Abstract Poster

Authors

null

Jay Parekh

UT Health San Antonio, San Antonio, TX

Jay Parekh , Soniya Abraham , Haripriya Andanamala , Asad Rehman , Paul Ahearn , Yaw Adjepong , Gregory Buller , Stacey Stein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 445)

DOI

10.1200/JCO.2024.42.3_suppl.445

Abstract #

445

Poster Bd #

A10

Abstract Disclosures

Similar Posters

First Author: Timothy J. Brown

First Author: Hirokazu Takahashi

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

First Author: Feng Wen

First Author: David Cosgrove